Priapism is a devastating complication of sickle cell disease (SCD) 
Efecto de la hidroxiurea en el priapismo en los hombres con enfermedad de células falciformes 
INTRODUCTION
Hydroxyurea (HU) is a disease-modifying agent in the management of sickle cell disease (SCD). Chronic HU therapy has shown sustained benefit in reversing or preventing chronic organ injury in SCD. Hydroxyurea reduces the rates of vaso-occlusive painful crises and acute chest syndrome and improves survival (1-3). Hydroxyurea, which is a nitric oxide (NO) donor, is thought to act prophylactically in priapism by increasing bioavailable NO levels (4). The drug has a unique advantage of being relatively inexpensive, requires only once daily dosing and is orally administered.
Priapism is a devastating complication of SCD typified by recurrent, prolonged, painful episodes of penile erection (5). Priapism occurs in over 40% of men with SCD, and erectile dysfunction is a consequence of prolonged episodes (6) . No standard of care exists for the prophylaxis of recurrent episodes.
Three prior case reports suggested a benefit of HU in the prevention of priapism (7) (8) (9) . Therefore, we sought to determine the association between HU therapy and the prevention of priapism episodes in men with SCD.
SUBJECTS AND METHODS
A retrospective case series was conducted between July 1 and September 30, 2014 to evaluate the association between priapism episodes and chronic HU use in men with SCD. The electronic database of the Sickle Cell Unit, The University of the West Indies (UWI), Mona, Jamaica, was searched for all male patients with SCD who had a recorded history of recurrent ischaemic priapism (active or remitted) and also had previous or active treatment with daily HU. All eligible patients were contacted by telephone, and a questionnaire on priapism frequency and duration was completed via an interviewer. The use of named prophylactic agents for priapism was also recorded.
Ethical approval was granted by the University Hospital of the West Indies/The University of the West Indies, Mona, Faculty of Medical Sciences Ethics Committee. Consent was granted by all patients and assent granted by parents of all minors.
The data were analysed with the Stata statistical software for Windows™ version 12 (College Station, TX 77845, United States of America).
RESULTS
Of the 15 male patients who fulfilled eligibility criteria, 10 with homozygous SCD of a mean age of 26.2 ± 10.7 years consented for the study. The mean age of the onset of HU use was 19.5 ± 11.04 years. The most frequent indication for HU use was prevention of recurrent painful crises (50%) and stroke (30%). The mean duration of HU use was 7.5 ± 5.1 years at a mean dose of 19.5 ± 7.3 mg/kg. Only two patients had received medical prophylaxis for priapism in the form of hormonal therapy (stilboestrol and pseudoephedrine).
Three patients had frequent priapism episodes, either daily or on alternate days at baseline. The baseline duration of the priapism episodes was over two hours in 50% of those interviewed, with 30% lasting over five hours.
One patient interviewed continued to have daily episodes of stuttering priapism while on HU; however, five patients had cessation of episodes while on HU therapy. Of the patients who continued to have priapism while on HU therapy, three had episodes lasting less than 30 minutes, one had episodes of an average duration of one hour, and only one patient continued to have episodes lasting over five hours.
DISCUSSION
The results suggested a possible association between chronic HU therapy and reduced frequency and duration of recurrent ischaemic priapism episodes in men with SCD. The mechanism of action of HU in preventing priapism episodes is presumed to be mediated through its ability to increase bioavailable NO levels. There is a constitutive deficiency of bioavailable NO in SCD. Hydroxyurea contains a NO moiety which is released through unknown mechanisms. Other investigators have revealed that therapy to restore NO homeostasis may reduce priapism in animal models of SCD (10) (11) (12) . This has translated into clinical effects with chronic therapy with phosphodiesterase inhibitors for SCD-associated priapism prophylaxis (13) . An additional effect of HU which may be beneficial in recurrent ischaemic priapism prophylaxis is its ability to increase HbF levels which reduces haemolysis (14) . This effect potentiates NO homeostasis in SCD. Hydroxyurea may show even greater promise for therapeutics in SCD-mediated priapism by possibly reducing enthothelin-1 mediated corporal fibrosis. Enthothelin-1 levels are elevated in SCD (15) , and since it is responsible for fibrosis in several organ systems, it is postulated to be responsible for corporal fibrosis in SCD (9). Anele et al recently reported a case of recovery from erectile dysfunction in a young man with SCD after a prolonged ischaemic priapism episode and administration of chronic HU therapy (9) .
Our study represents a small sample cross-sectional study which may be limited by recall bias. The varying natural history of priapism in men with SCD prevents us from reliably attributing the amelioration of priapism episodes completely to the effect of HU. However, we think that the mechanism of action of HU and the demonstrated association of HU therapy with priapism episodes are strong enough to warrant further controlled clinical trials to evaluate prophylactic effects.
